ReviewPolymers2023
Sericin from Fibroin-Deficient Silkworms Served as a Promising Resource for Biomedicine.
Review in Polymers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 31 citations in OpenAlex.
- Process-Driven Modulation of Structure and Cytocompatibility in Electrospun Silk Fibroin Membranes through Controlled Degumming.ACS omega · 2026Article
- Review
- Article
- Recycled Sericin Biopolymer in Biotechnology and Bioelectronics.Bioengineering (Basel, Switzerland) · 2025Review
- Silk Protein Gene Engineering and Its Applications: Recent Advances in Biomedicine Driven by Molecular Biotechnology.Drug design, development and therapy · 2025Review
- Characterization and comparative analysis of sericin protein 150 in Bombyx mori.Scientific reports · 2024Article
- Article
- A Sterile, Injectable, and Robust Sericin Hydrogel Prepared by Degraded Sericin.Gels (Basel, Switzerland) · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Sericin, a fascinating natural biomaterial derived from silkworms, has received increasing interest in recent years for its unique bioactivity and high compatibility. Silkworms can be divided into wild-type or silk fibroin-deficient mutants according to whether they synthesize and secrete silk fibroin. Silk fibroin-deficient mutant silkworms and their cocoons are convenient for us to obtain diverse and high-quality sericin, which has been applicated in various fields such as cell culture, tissue engineering, drug delivery, and cosmetics. Here, we present an overview of our silkworm varieties resources, especially silk fibroin-deficient mutant silkworms. We optimized various extraction methods of sericin and summarized the characteristics and advantages of sericin. Finally, we developed and discussed a series of sericin-based biomaterials for promising applications for a diverse set of needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.